Doxorubicin (Adriamycin) HCl is an antineoplastic agent used in the treatment of a wide range of cancers, including hematological malignancies, many types of carcinoma, and soft tissue sarcomas. Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. Doxorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication. In studies with isolated nuclei, adriamycin was also a more potent inhibitor of DNA synthesis than RNA synthesis. However, with intact cells, adriamycin inhibited both DNA and RNA synthesis to about the same extent. The inhibition produced by adriamycin on RNA synthesis in intact cells was greater than that observed in the cell-free systems. Adriamycin inhibited protein synthesis in a cell-free system consisting of polyribosomes, transfer RNA, and enzymes but did not inhibit protein synthesis in intact cells. Combination therapy experiments with sirolimus (rapamycin) and doxorubicin have shown promise in treating Akt-positive lymphomas in mice.
Elife. 2021 Jun 28;10:e65150.
Resistance to different anthracycline chemotherapeutics elicits distinct and actionable primary metabolic dependencies in breast cancer
Doxorubicin HCL purchased from AbMole
Mol Med Rep. 2021 Mar;23(3):219.
Shengxian decoction decreases doxorubicin‑induced cardiac apoptosis by regulating the TREM1/NF‑κB signaling pathway
Doxorubicin HCL purchased from AbMole
2020 Aug.
Blockage of AMPK-ULK1 pathway mediated autophagy promotes cell apoptosis to increase doxorubicin sensitivity in breast cancer (BC) cells: an in vitro study
Doxorubicin HCL purchased from AbMole
PLoS One. 2017 Jul 13;12(7):e0181340.
Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing
Doxorubicin HCL purchased from AbMole
Biomaterials 2012 Jun;4345-52.
Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin
Doxorubicin HCL purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | Human choriocarcinoma cell line |
Preparation method | Briefly, cells were plated on 96-well plates (10,000 cells/well) and a day after (cell culture 80% confluent) were exposed to doxorubicin (0–8 mM), L-DOX (0–8 mM) or PL-DOX (0–200 mM) in non-supplemented serum-free growth medium for 4 h. After exposure, the cells were washed and further incubated for 20 h. |
Concentrations | 0–8 µM |
Incubation time | 24 h |
Animal Experiment | |
---|---|
Animal models | Male Sprague-Dawley rats |
Formulation | |
Dosages | 4 mg/kg |
Administration | i.v. |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Molecular Weight | 579.98 |
Formula | C27H29NO11.HCl |
CAS Number | 25316-40-9 |
Purity | 100.0% |
Solubility | DMSO 45 mg/mL Water 30 mg/mL |
Storage | 2-8°C, protect from light, dry, sealed |
Related Topoisomerase Products |
---|
Rubitecan
Rubitecan is a topoisomerase I inhibitor extracted from the bark and leaves of the Camptotheca acuminata tree, which is native to China. Rubitecan is an oral camptothecin with antitumour activity. |
(S)-10-Hydroxycamptothecin
10-Hydroxycamptothecin is a DNA topoisomerase I inhibitor with potent anti-tumor activity. |
WAY-272160
WAY-272160 is a inhibitory activities for topoisomerase II and HER2 |
Gatifloxacin hydrochloride
Gatifloxacin (AM-1155, CG5501, BMS-206584, PD135432) hydrochloride is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases with IC50 of 13.8 μg/ml and 0.109 μg/ml for S. aureus topoisomerase IV and E. coli DNA gyrase, respectively. |
Aldoxorubicin
Aldoxorubicin (INNO-206) is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.